摘要
目的研究冠心病患者血清肿瘤坏死因子a(TNF-α)和半胱氨酸蛋白酶抑制剂C(CysC)的水平,观察加用或不加用血塞通治疗对血清TNF-α和CysC的影响。方法将186例确诊为冠心病稳定性心绞痛的患者随机分为标准治疗组和标准治疗加血塞通治疗组,治疗12周,另选择90例我院健康体检正常人作为健康对照组。比较3组治疗前及两治疗组治疗前、后血清TNF-α和CysC的浓度变化。结果①TNF-α治疗前,两治疗组血清TNF-α无显著差异,但均高于健康对照组,差异有显著性(P<0.05);各组与治疗前比较,治疗后两组患者血清TNF-α均降低(P<0.05),但血塞通组较标准治疗组TNF-α下降更明显(P<0.05)。②CysC治疗前,两治疗组血清CysC无显著差异,但均低于健康对照组,差异有显著性(P<0.05);各组与治疗前比较,治疗后两组患者血清CysC均明显升高(P<0.05),但血塞通组较标准治疗组CysC升高更明显(P<0.05)。结论冠心病患者存在血清TNF-α升高和CysC浓度降低的改变,加用血塞通组比标准治疗组血清TNF-α浓度下降更明显,而CysC浓度升高明显,说明血塞通除了具有扩血管作用,对冠心病患者的炎症反应也有显著疗效。
[Objective]To investigate the level of Cystatin C and Tumor necrosis factor-α in patients with coronary artery disease （CAD） and the changes after standard therapy with or without Xuesetong. [Methods]The subjects were recruited and diagnosed as by coronary angiographic results.186 patients were divided into two groups. Standard therapy of CAD （n=93） was treated and with Xuesetong over 12 weeks . In addition, 90 normal cases as the control group were choosen.[Results]TNF-α： Before treatment, two therapy group were at the same level on TNFα but significant higher than control group. After treatment, TNF-α decreases significantly in Xuesetong group. Cys C Before treatment, two therapy group were at the same level on CysC but significantly lower than the control group. After treatment, CysC increase significant in Xuesetong group. [Conclusion]Serum Cys C and TNF-α concentrations in CAD are different from the healthy. After treatment of Xuesetong, serum TNF-α concentration is significantly decreased and serum Cys C concentration significantly increased.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2010年第10期1529-1532,1536,共5页
China Journal of Modern Medicine
